CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection

Timely diagnosis is of great benefit to improve the survival rate cancer patients. Body fluid biomarker detection a critical kind noninvasive method for diagnosis. Nevertheless, traditional methods always rely on large-scale instrument and involve sophisticated operation. Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein (CRISPR/Cas)-based in vitro can simplify procedures sensitivity specificity, holding promise as next-generation molecular diagnostic technology. In this Feature, we introduce working mechanisms different kinds CRISPR/Cas systems biosensing CRISPR/Cas-mediated strategies biomarkers including nucleic acids, proteins, extracellular vesicles. addition, perspective challenges CRISPR/Cas-based are discussed.